Q: Are we hoping to improve upon these results and become part of the cocktail or are we hoping for something else?

I think yes, we are trying to improve on the current standard of care best results for third line therapy by adding leronlimab to this cocktail. We are hoping LL will improve on this 10.8 months mOS. We will be testing both 350 mg dose and 700 mg (if/after 350 proves safe).

From the study you referenced:

https://www.nejm.org/doi/full/10.1056/NEJMoa2214963

Quote:

---

Patients with metastatic colorectal cancer generally receive first- and second-line treatment with fluorouracil-based chemotherapy (with oxaliplatin and irinotecan), vascular endothelial growth factor (VEGF)–based therapy (mainly bevacizumab), and epidermal growth factor receptor (EGFR)–targeted therapies (the last in patients with RAS wild-type tumors).1,2 Patients who have disease progression after receiving these therapies are considered to have refractory disease; however, many of these patients have a good performance status and may be considered for further therapy.

---

Q2: PR paragaph

Enrollment criteria for our study:
actually have a tumor that can be measured
previously failed chemo and anti-VEGF (bevacizumab) and anti-EGFR (if appropriate to that patient's cancer)
tumor must have CCR5 marker (or else why are we treating with LL, the anti-CCR5 drug?)

Q3: what do we expect of LL?

Success would be significantly extending mOS past 10.8 months. Even 2-3 months longer is progress. It would probably be good to see a dose response, meaning 700 mg is better than 350 mg.